Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Leukemia ; 34(5): 1383-1393, 2020 05.
Article in English | MEDLINE | ID: mdl-31796914

ABSTRACT

Light chain (AL) amyloidosis is a progressive, degenerative disease characterized by the misfolding and amyloid deposition of immunoglobulin light chain (LC). The amyloid deposits lead to organ failure and death. Our laboratory is specifically interested in cardiac involvement of AL amyloidosis. We have previously shown that the fibrillar aggregates of LC proteins can be cytotoxic and arrest the growth of human RFP-AC16 cardiomyocytes in vitro. We showed that adipose-derived mesenchymal stromal cells (AMSC) can rescue the cardiomyocytes from the fibril-induced growth arrest through contact-dependent mechanisms. In this study, we examined the transcriptome changes of human cardiomyocytes and AMSC in the presence of AL amyloid fibrils. The presence of fibrils causes a 'priming' immune response in AMSC associated with interferon associated genes. Exposure to AL fibrils induced changes in the pathways associated with immune response and extracellular matrix components in cardiomyocytes. We also observed upregulation of innate immune-associated transcripts (chemokines, cytokines, and complement), suggesting that amyloid fibrils initiate an innate immune response on these cells, possibly due to phenotypic transformation. This study corroborates and expands our previous studies and identifies potential new immunologic mechanisms of action for fibril toxicity on human cardiomyocytes and AMSC rescue effect on cardiomyocytes.


Subject(s)
Biomarkers/analysis , Immunoglobulin Light Chains/immunology , Immunoglobulin Light-chain Amyloidosis/immunology , Inflammation/immunology , Mesenchymal Stem Cells/immunology , Myocytes, Cardiac/immunology , Apoptosis , Cell Proliferation , Cells, Cultured , Gene Expression Profiling , Humans , Immunoglobulin Light-chain Amyloidosis/metabolism , Immunoglobulin Light-chain Amyloidosis/pathology , Inflammation/metabolism , Inflammation/pathology , Mesenchymal Stem Cells/metabolism , Mesenchymal Stem Cells/pathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology
2.
Methods Mol Biol ; 1873: 123-153, 2019.
Article in English | MEDLINE | ID: mdl-30341607

ABSTRACT

Common biophysical techniques like absorption and fluorescence spectroscopy, microscopy, and light scattering studies have been in use to investigate fibril assembly for a long time. However, there is sometimes a lack of consensus from the findings of an individual technique when compared in parallel with the other techniques. In this chapter, we aim to provide a concise compilation of techniques that can effectively be used to obtain a comprehensive representation of the structural, aggregation, and toxicity determinants in immunoglobulin light chain amyloidosis. We start by giving a brief introduction on amyloid assembly and the advantages of using simple and readily available techniques to study aggregation. After an overview on preparation of protein to set up parallel experiments, we provide a systematic description of the in vitro techniques used to study aggregation in AL protein. Additionally, we thoroughly discuss the steps needed in our experience during the individual experiments for better reproducibility and data analysis.


Subject(s)
Amyloid/chemistry , Biological Assay , Immunoglobulin Light Chains/chemistry , Amyloid/metabolism , Amyloidogenic Proteins/chemistry , Amyloidogenic Proteins/metabolism , Amyloidosis/diagnosis , Apoptosis , Benzothiazoles/chemistry , Benzothiazoles/metabolism , Biological Assay/methods , Chromatography, Gel , Chromatography, High Pressure Liquid , Circular Dichroism , Dynamic Light Scattering , Immunoglobulin Light Chains/metabolism , Particle Size , Spectrometry, Fluorescence
3.
Chem Commun (Camb) ; 54(76): 10664-10674, 2018 Sep 20.
Article in English | MEDLINE | ID: mdl-30087961

ABSTRACT

Light chain (AL) amyloidosis is a devastating, complex, and incurable protein misfolding disease. It is characterized by an abnormal proliferation of plasma cells (fully differentiated B cells) producing an excess of monoclonal immunoglobulin light chains that are secreted into circulation, where the light chains misfold, aggregate as amyloid fibrils in target organs, and cause organ dysfunction, organ failure, and death. In this article, we will review the factors that contribute to AL amyloidosis complexity, the findings by our laboratory from the last 16 years and the work from other laboratories on understanding the structural, kinetics, and thermodynamic contributions that drive immunoglobulin light chain-associated amyloidosis. We will discuss the role of cofactors and the mechanism of cellular damage. Last, we will review our recent findings on the high resolution structure of AL amyloid fibrils. AL amyloidosis is the best example of protein sequence diversity in misfolding diseases, as each patient has a unique combination of germline donor sequences and multiple amino acid mutations in the protein that forms the amyloid fibril.


Subject(s)
Amyloid/metabolism , Amyloidogenic Proteins/metabolism , Immunoglobulin Light Chains/metabolism , Immunoglobulin Light-chain Amyloidosis/physiopathology , Protein Multimerization , Amyloid/chemistry , Amyloid/genetics , Amyloidogenic Proteins/chemistry , Amyloidogenic Proteins/genetics , Gene Rearrangement , Glycosaminoglycans/metabolism , Humans , Immunoglobulin Light Chains/chemistry , Immunoglobulin Light Chains/genetics , Mutation , Plasma Cells/metabolism , Protein Stability
4.
Cytotherapy ; 19(12): 1426-1437, 2017 12.
Article in English | MEDLINE | ID: mdl-29037943

ABSTRACT

BACKGROUND AIMS: Light chain (AL) amyloidosis is a protein misfolding disease characterized by extracellular deposition of immunoglobulin light chains (LC) as amyloid fibrils. Patients with LC amyloid involvement of the heart have the worst morbidity and mortality. Current treatments target the plasma cells to reduce further production of amyloid proteins. There is dire need to understand the mechanisms of cardiac tissue damage from amyloid to develop novel therapies. We recently reported that LC soluble and fibrillar species cause apoptosis and inhibit cell growth in human cardiomyocytes. Mesenchymal stromal cells (MSCs) can promote wound healing and tissue remodeling. The objective of this study was to evaluate MSCs to protect cardiomyocytes affected by AL amyloid fibrils. METHODS: We used live cell imaging and proteomics to analyze the effect of MSCs in the growth arrest caused by AL amyloid fibrils. RESULTS: We evaluated the growth of human cardiomyocytes (RFP-AC16 cells) in the presence of cytotoxic LC amyloid fibrils. MSCs reversed the cell growth arrest caused by LC fibrils. We also demonstrated that this effect requires cell contact and may be mediated through paracrine factors modulating cell adhesion and extracellular matrix remodeling. To our knowledge, this is the first report of MSC protection of human cardiomyocytes in amyloid disease. CONCLUSIONS: This important proof of concept study will inform future rational development of MSC therapy in cardiac LC amyloid.


Subject(s)
Amyloid/toxicity , Immunoglobulin Light-chain Amyloidosis/pathology , Mesenchymal Stem Cells/cytology , Myocytes, Cardiac/pathology , Amyloid/metabolism , Apoptosis , Cells, Cultured , Coculture Techniques , Humans , Immunoglobulin Light Chains/metabolism , Immunoglobulin Light-chain Amyloidosis/therapy , Mesenchymal Stem Cells/metabolism , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism
5.
Sci Rep ; 6: 29297, 2016 07 07.
Article in English | MEDLINE | ID: mdl-27384401

ABSTRACT

Mycobacterium tuberculosis is a successful intracellular pathogen. Numerous host innate immune responses signaling pathways are induced upon mycobacterium invasion, however their impact on M. tuberculosis replication is not fully understood. Here we reinvestigate the role of STAT3 specifically inside human macrophages shortly after M. tuberculosis uptake. We first show that STAT3 activation is mediated by IL-10 and occurs in M. tuberculosis infected cells as well as in bystander non-colonized cells. STAT3 activation results in the inhibition of IL-6, TNF-α, IFN-γ and MIP-1ß. We further demonstrate that STAT3 represses iNOS expression and NO synthesis. Accordingly, the inhibition of STAT3 is detrimental for M. tuberculosis intracellular replication. Our study thus points out STAT3 as a key host factor for M. tuberculosis intracellular establishment in the early stages of macrophage infection.


Subject(s)
Macrophages/metabolism , Nitric Oxide Synthase/metabolism , STAT3 Transcription Factor/metabolism , Tuberculosis/metabolism , Animals , Cell Line , Chemokine CCL4/metabolism , Humans , Immunity, Innate/immunology , Interferon-gamma/metabolism , Interleukin-10/metabolism , Interleukin-6/metabolism , Macrophages/microbiology , Mice , Mycobacterium tuberculosis/immunology , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , RAW 264.7 Cells , Signal Transduction/physiology , Tuberculosis/immunology , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...